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STATINS AND COLORECTAL CANCER: IS THERE A LINK?
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Medical School, Boston, MA, USA
OBJECTIVES: Studies evaluating the association between statins and colorectal
cancer (CRC) have used various methods to address bias and have reported mixed
findings. We sought to assess the association in a large cohort of residents in
Emilia-Romagna, Italy, usingmultiplemethods to address different sources of con-
founding. We also sought to explore potential effect measure modification by sex.
METHODS:Weconducted a retrospective population-based new-user cohort study
using the 2003–2010 longitudinal healthcare database of Emilia-Romagna, Italy.
This comprehensive database contains information on healthcare services ren-
dered to the population, including hospital, outpatient pharmacy and specialty
data. We identified all initiators of statins; initiators of glaucoma medications
served as the comparison group to account for confounding by healthy user bias.
We followed patients longitudinally to identify CRC cases in hospital discharge
data. We used multivariable Cox regression analyses to adjust for confounding by
CRC risk factors and we conducted a sensitivity analysis using propensity score
matching. RESULTS: Among 215,963 statin initiators, we observed 1870 cases of
CRC, reflecting a crude incidence rate of 222.2 cases per 100,000 person-years. After
multivariable adjustment, initiators of statins had a lower incidence rate of CRC as
compared to initiators of glaucoma drugs (hazard ratio, 0.79; 95% CI, 0.69 to 0.90). In
sex-stratified analyses we observed a protective effect in men (hazard ratio, 0.77;
95% CI, 0.67 to 0.88) but not in women (hazard ratio 0.96; 95% CI, 0.82 to 1.1). Results
were similar in propensity score analyses. CONCLUSIONS: After adjusting for ob-
served risk factors, statin initiation versus glaucoma drug initiationwas associated
with a reduced risk of CRC in men but not in women. While this study is subject to
many limitations, it corroborates a previous study that found sex differences in the
association between statins and CRC.
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DEVELOPMENT OF A PATIENT-REPORTED OUTCOME INSTRUMENT IN BRAIN
METASTASES: THE BRAIN METASTASES SYMPTOM AND IMPACT
QUESTIONNIARE (BASIQ)
Lasch KE1, Ganguli A2, Bonthapally V2, Pompilus F1, Delbecque L1, Fitzgerald K1, Ray S2
1Adelphi Values, Boston, MA, USA, 2Abbott Laboratories, Abbott Park, IL, USA
OBJECTIVES: Patient-reported outcomes (PRO) instruments currently used for
patients with brain metastases (BM) have not been developed with adequate
patient input from the appropriate population. The objective of this study was
to develop a new PRO in this population. METHODS: The BASIQ was developed
according to the FDA PRO Guidance. A literature review, seven expert inter-
views, and 19 in-depth interviews with BM patients were conducted to identify
the symptoms and impacts of BM important to this population and generate an
initial version of the BASIQ. Twenty face-to-face cognitive interviews (CIs) were
conducted to assess the content validity of the BASIQ and to assess the under-
standability, relevance, wording, and importance of items and, if necessary,
revise it. RESULTS: The initial 23-item BASIQ included a 7-item event log with a
yes/no response (assessing vision, reading, nausea, numbness, needing to stay
in bed, falling, fainting), 7-item daily symptom section (assessing severity of
headache, memory, balance, physical weakness, dizziness, tiredness, energy)
on an 11-point NRS, and a 9-item impact section (assessing speaking certain
words, putting ideas into words, staying focused on a topic, walking, under-
standing words read/heard, following a story in a book/on TV, doing things
around the house, bathing, dressing). During the CIs, most of the patients re-
ported that the instrument was easy to understand, of adequate length and
format and did not contain any difficult words. Based on the CIs, items were
deleted, modified, or included as impacts rather than symptoms. A revised
18-item BASIQ used a 24-hour recall period and an 11-point NRS assessing
severity. CONCLUSIONS: Robust qualitative methods used to identify the symp-
toms and impacts of patients with BM led to the development of a much needed
PROmeasure in BM. Additional qualitative and quantitative research is planned to
further support the use of the tool in clinical research.
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MULTI-LEVEL MODELING OF OVERALL MORTALITY FOR MEN DIAGNOSED
WITH PROSTATE CANCER IN FLORIDA
Xiao H1, Tan F2, Gwede C3, Huang Y4, Goovaerts P5, Adunlin G1, Ali A1
1Florida A&M University, Tallahassee, FL, USA, 2Indiana University-Purdue University,
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OBJECTIVES: To identify individual and contextual factors contributing to overall
prostate cancer mortality in Florida. METHODS: Using men diagnosed with pros-
tate cancer between 10/1/2001 and 12/31/2007 in the Florida Cancer Data System,
the following patient’s information were extracted: demographics, type of health
insurance at diagnosis, tumor stage, treatment and all-cause death. Census-tract
level socioeconomic status & farm house presence were extracted from Census
2000 and linked to patient data. Comorbidity was computed following Elix-
hauser Index. Multi-level logistic regression was conducted to identify signifi-
cant individual and contextual factors to overall mortality among the prostate
cancer patients. RESULTS: 60,497 patients were identified, among whom 8,125
died. Being older at diagnosis, unmarried, current smoker, uninsured, diag-
nosed at late stage, undifferentiated or unknown tumor grade and poorly dif-
ferentiated tumor grade were significantly associated with overall mortality.
Interaction between stage and grade showed more detrimental late-stage effect
as grade worsened and increasingly disadvantageous grade effect at later stage
of diagnosis. Low educational attainment of the census tract where patient lived
was significantly related to mortality. After adjusting for age, stage and tumor
grade, patients who received other treatment categories, except for those who
received combined surgery and radiation therapy, were more likely to die com-
pared to those received surgery only. A large number of major comorbidities
such as congestive heart failure, peripheral vascular disorder, paralysis, chronic
pulmonary disease, diabetes, renal failure, liver disease, a number of other
malignancies, etc. were associated with increased risk of mortality.
CONCLUSIONS: Multi-level modeling allows examination of factors at various
levels in relation to patient overall mortality. Patient’s demographics, disease
stage, comorbidity and available treatment are associated with overall mortal-
ity among prostate cancer patients. Although disease specific mortality was not
examined, these findings suggest the importance of careful consideration of
multiple patient and disease characteristics in treatment decision making.
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TOTAL HEALTH CARE COSTS FOR COLORECTAL CANCER PATIENTS
FOLLOWING METASTATIC DIAGNOSIS
Chastek B1, Kulakodlu M1, Valluri S2, Seal B2
1OptumInsight, Eden Prairie, MN, USA, 2Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ,
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OBJECTIVES: To evaluate health care costs incurred by CRC patients post
metastases. METHODS: Adult patients with a CRC diagnosis between January 1,
2005 andMay 31, 2010 were identified from the Impact Intelligence Oncology Man-
agement (IIOM) registry. Patients with stage 4 CRC at diagnosis or development of
metastasis were included. Registry data included original stage and date of diag-
nosis. Linked health care claims from a large US health insurance database affili-
ated with OptumInsight were used to identify health care costs and patient char-
acteristics. To account for survival, Lin’s regression of total 4-year health care costs
was conducted comparing stage and controlling for patient characteristics. Vari-
able follow-up ended at earliest of death, disenrollment from health plan, or study
end (11/30/10). RESULTS:A total of 598 patients, followed for an average of 653 days
after first evidence of metastases, were included. At original study diagnosis, 310
patients were stage 4, 197 were unknown stage, and 91 stage 0-3. Mean unadjusted
total cost was $252,200; outpatient hospital visits (excluding radiation, surgery)
comprised the bulk of that, at amean cost of $71,334. Hospitalization costs, with or
without surgery (mean, $56,862), accounted for 33% of unadjustedmean totalmed-
ical cost ($176,135). Outpatient office visits, chemotherapy, and biologics were also
costly (mean, $36,217, $31,112, $38,276, respectively). On Lin’s regression, mean
predicted total 4-year costs were: $361,197 (stage 4), $267,728 (originally stage 3;
p0.014 vs stage 4), $319,146 (originally stage 0-2; p0.514), and $351,833 (originally
unknown stage; p0.757). Looking at the entire IIOMpopulation (n1,298), patients
with metastasis, either at index diagnosis or later, had significantly greater costs
than patients whose CRC did not metastasize (difference: $138,326; p0.001).
CONCLUSIONS: Predicted 4-year costs were highest among patients who initially
presented with stage 4 CRC, and lowest among patients who presented with stage
3 and developed metastatic disease.
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